Evidence map›Paper›PMID 26599131›Full record

Trial reportAddiction (Abingdon, England)2016

Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.

Yih-Ing Hser, Elizabeth Evans, David Huang, Robert Weiss, Andrew Saxon, Kathleen M Carroll, George Woody, David Liu, Paul Wakim, Abigail G Matthews and 5 more

Open access · greenAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Addiction (Abingdon, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
133citing papers in PubMed, 2 pooled it
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

133 citing papers in PubMed, 2 syntheses or guidelines pooled it, 212 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2018
    Trial
  18. Trial
  19. Trial
  20. Trial

73 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 1 country.

Yih-Ing HserUniversity of California, Los Angeles, CA, USA.
Elizabeth EvansUniversity of California, Los Angeles, CA, USA.
David HuangUniversity of California, Los Angeles, CA, USA.
Robert WeissUniversity of California, Los Angeles, CA, USA.
Andrew SaxonVeterans Affairs Puget Sound Health Care System, Seattle, WA, USA.
Kathleen M CarrollYale University School of Medicine, New Haven, CT, USA.
George WoodyUniversity of Pennsylvania, Philadelphia, PA, USA.
David LiuNational Institute on Drug Abuse, Bethesda, MD, USA.
Paul WakimNational Institute on Drug Abuse, Bethesda, MD, USA.
Abigail G MatthewsEmmes Corporation, Rockville, MD, USA.
Mary Hatch-MailletteUniversity of Washington, Seattle, WA, USA.
Eve JelstromEmmes Corporation, Rockville, MD, USA.
Katharina WiestCODA, Inc., Portland, OR, USA.
Paul McLaughlinHartford Dispensary, Hartford, CT, USA.
Walter LingUniversity of California, Los Angeles, CA, USA.
University of California, Los Angeles · USEmmes (United States) · USNational Institute on Drug Abuse · USOregon Medical Research Center · USUniversity of Hartford · USUniversity of Pennsylvania · USUniversity of Washington · USVA Puget Sound Health Care System · USYale University · US

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
The National Drug Abuse Treatment Clinical Trials NetworkU10DA013045 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LING, WALTER NMN · 1999 to 2015
$52.6M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9M
Delaware Valley Node of the Clinical Trials NetworkU10DA013043 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI WOODY, GEORGE EDWARD · 1999 to 2015
$25.8M
Western States Node of the National Drug Abuse Treatment Clinical Trials NetworkU10DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCARTY, DENNIS, SORENSEN, JAMES L · 2002 to 2015
$25.2M
Clinical Trials Network: Pacific Northwest Node (CTN-0082, -0131, -0139 and dissemination library)UG1DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI Mary Akiko Hatch, John M. Roll · 2015 to 2026
$19.8M
CLINICAL TRIALS NETWORK: NEW ENGLAND NODEU10DA013038 · NIDA · YALE UNIVERSITY · PI CARROLL, KATHLEEN M. · 1999 to 2010
$17.3M
STATISTICAL SUPPORT/DATA MANAGEMENT COREP30DA016383 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HSER, YIH-ING · 2005 to 2015
$8.6M
NIAID NIH HHS P30 AI028697NIDA NIH HHS P30 DA016383NIDA NIH HHS P30DA016383NIDA NIH HHS U10 DA013038NIDA NIH HHS U10 DA013043NIDA NIH HHS U10 DA013045NIDA NIH HHS U10 DA 015815NIDA NIH HHS U10 DA015815NIDA NIH HHS U10 DA01714NIDA NIH HHS U10 DA13038NIDA NIH HHS U10 DA13043NIDA NIH HHS U10 DA13045NIDA NIH HHS UG1 DA013035NIDA NIH HHS UG1 DA013714
6 · The paper itself

Abstract

aimsTo compare long-term outcomes among participants randomized to buprenorphine or methadone. DESIGN, SETTING AND

participantsFollow-up was conducted in 2011-14 of 1080 opioid-dependent participants entering seven opioid treatment programs in the United States between 2006 and 2009 and randomized (within each program) to receive open-label buprenorphine/naloxone or methadone for up to 24 weeks; 795 participants completed in-person interviews (~74% follow-up interview rate) covering on average 4.5 years. MEASUREMENTS: Outcomes were indicated by mortality and opioid use. Covariates included demographics, site, cocaine use and treatment experiences.

findingsMortality was not different between the two randomized conditions, with 23 (3.6%) of 630 participants randomized to buprenorphine having died versus 26 (5.8%) of 450 participants randomized to methadone. Opioid use at follow-up was higher among participants randomized to buprenorphine relative to methadone [42.8 versus 31.7% positive opioid urine specimens, P < 0.01, effect size (h) = 0.23 (0.09, 0.38); 5.8 days versus 4.4 days of past 30-day heroin use, P < 0.05, effect size (d) = 0.14 (0.00, 0.28)]. Opioid use during the follow-up period by randomization condition was also significant (F(7,39,600) = 3.16; P < 0.001) due mainly to less treatment participation among participants randomized to buprenorphine than methadone. Less opioid use was associated with both buprenorphine and methadone treatment (relative to no treatment); no difference was found between the two treatments. Individuals who are white or used cocaine at baseline responded better to methadone than to buprenorphine.

conclusionsThere are few differences in long-term outcomes between buprenorphine and methadone treatment for opioid dependence, and treatment with each medication is associated with a strong reduction in opioid use.

Indexed as

AdolescentAdultAnalgesics, OpioidBuprenorphine, Naloxone Drug CombinationFemaleFollow-Up StudiesHumansMaleMethadoneMiddle AgedNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersRandom AllocationTreatment OutcomeYoung AdultAnalgesics, OpioidBuprenorphine, Naloxone Drug CombinationMethadoneNarcotic AntagonistsBuprenorphinelongitudinalmethadonemortalityopioid dependenceopioid useoutcomes

Identifiers

PMID26599131
PMCPMC4801718
OpenAlexW2173844711

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.